Patent application number | Description | Published |
20090215697 | COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS - The present invention concern a composition or a patch adapted for the prophylactic or therapeutic treatment by continuous subcutaneous administration of a subject suffering from atherosclerosis, comprising an effective amount of at least one epitope derived from a protein present in the atherosclerotic plaque, whereby administration of said at least one epitope to said subject induces a specific regulatory immune response, preferably a Treg response. | 08-27-2009 |
20090325194 | USE OF SPLA2 ACTIVITY FOR THE DIAGNOSIS OF A CARDIOVASCULAR EVENT - A method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, includes:—determining the sPLA2 activity of the patient as a first risk marker—determining at least the value of a second risk marker chosen among CRP level, IgM IC of apo B 100 level or IgM MDA-LDL level—determining the ratio (odds ratio) between the value of the sPLA2 activity and the value of the second risk marker and comparing it to a predetermined odds ratio, the odds ratio compared to the predetermined odds ratio being indicative of an increased risk of mortality or of a cardiac and/or vascular event. A new micro method adaptation for automated fluorimetric measurement of serum secretory phospholipase A2 is also disclosed. | 12-31-2009 |
20100291028 | USE OF IL-18 INHIBITORS FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL VASCULAR DISEASES - The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation. | 11-18-2010 |
20110229919 | COMBINATION OF SPLA2 ACTIVITY AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT. - A method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, includes:
| 09-22-2011 |
20120171705 | COMBINATION OF SPLA2 ACTIVITY AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT - The use of a combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event or for the monitoring of a cardiovascular disease. | 07-05-2012 |
20120264146 | COMBINATION OF SPLA2 ACTIVITY AND LP(A) CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT - The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: -measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) s PLA2 activity and b) Lipoprotein(a), -combining said measurements, the combined value of s PLA2 activity and Lp(a) being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event. | 10-18-2012 |
20120321650 | COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS - Epitopes derived from a protein present in an atherosclerotic plaque, such as apolipoprotein B-100, are presented. The epitopes can be used in a method of treating atherosclerosis by continuous subcutaneous or transcutaneous administration of a therapeutically effective amount of the epitope to a subject. Administering the epitope to the subject can induce a specific regulatory immune response, such as a Treg response. A composition or patch containing the epitope and adapted for the prophylactic or therapeutic treatment of a subject are also presented. | 12-20-2012 |
20150132771 | COMBINATION OF SPLA2 ACTIVITY AND LP(A) CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT - The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) s PLA2 activity and b) Lipoprotein(a), —combining said measurements, the combined value of s PLA2 activity and Lp(a) being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event. | 05-14-2015 |